Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

Abstract: A method for treating a surface of a fluorinated silicone-containing ophthalmic device is provided, the method comprising plasma treating the fluorinated silicone-containing ophthalmic device with a hydrogen-containing atmosphere in the presence of an oxidizing source thereby increasing the wettability and/or biocompatibility of the device.

Abstract: A contact lens is coated with a first polymer, such as a boronic acid-containing copolymer, having affinity to mucin, and a second polymer. The second polymer improves initial comfort of the contact lens. During wear of the contact lens, the second polymer is removed from the contact lens, by blinking and/or tear fluids, and mucin complexes with the first polymer on the contact lens surface.

Abstract: A method for treating the surface of a fluorinated biomedical device is provided comprising the steps of (a) plasma treating the fluorinated biomedical device with a hydrogen-containing atmosphere to reduce the fluorine or C—F bonding content of the fluorinated biomedical device; and (b) subjecting the hydrogen plasma treated surface to a plasma-polymerization reaction in a hydrocarbon-containing atmosphere to form a polymeric carbonaceous layer on the surface of the biomedical device.

Abstract: A silicone contact lens has a silicate coating on at least one of the contact lens surfaces. The silicate coating is anchored to the bulk silicone contact lens material with a non-silicone polymer layer.

Abstract: At least one of the surfaces of a silicone contact lens is a wrinkled surface, providing the contact lens surface with a desired topography. The wrinkled surface may include random ridges, either over the entire surface of the lens, or in a desired pattern on the surface of the lens.

Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to extract the polymerized medical devices with water. This avoids the use of organic solvents as is typical in the art. The polymeric compositions comprise polymerized cationic hydrophilic siloxanyl monomers prepared by the process disclosed herein.

Abstract: A method of reducing foam formation and improving odor in ophthalmic solutions, such as multipurpose cleaning and conditioning solutions and contact lens packing solutions. The ophthalmic solutions contain surfactant and aroma compound in an amount effective to decrease foam formation. The aroma compound has a low molecular weight and pleasing smell.

Abstract: A lens with a colored portion is composed of a lens-forming polymer having a front lens surface and a back lens surface. A colorant is applied to at least one of these surfaces, and these surfaces may be coated with a coating layer composed of a material different than the lens-forming polymer. In the case of a cosmetic contact lens, the colorant may be applied in an annular ring pattern corresponding to an iris, so that the colorant pattern masks and changes the apparent color of the natural iris when the contact lens is worn.

Abstract: A lens with a colored portion is composed of a lens-forming polymer having a front lens surface and a back lens surface. A colorant is applied to at least one of these surfaces, and these surfaces may be coated with a coating layer composed of a material different than the lens-forming polymer. In the case of a cosmetic contact lens, the colorant may be applied in an annular ring pattern corresponding to an iris, so that the colorant pattern masks and changes the apparent color of the natural iris when the contact lens is worn.

Abstract: A method for inhibiting the ability of a biomaterial to sorb cationic antimicrobials comprising treating the surface of said biomaterial with a cationic polysaccharide.

Abstract: The present invention is directed to a biguanide-containing disinfecting solutions effective in inactivating bacteria endospores on surfaces, air-borne or in water. The methods of using the present invention are directed to disinfecting endospore laden surfaces, air and water with the subject biguanide-containing solutions.

Abstract: The present invention is directed to a product and a method of making that product. The product is a unique bubble making solution that when bubbles are formed each bubble is interconnected to another bubble by a string of bubble solution. Admittedly, a portion of the bubble solution is known to those of ordinary skill in the art. That known portion is referred to as the fundamental bubble solution and it comprises at least one surfactant, at least one plasticizer, and water. From that fundamental bubble solution, the inventors add an effective amount of an organic polymeric resin having a molecular weight greater than 3 million. With that high molecular weight polymer, each formed bubble is interconnected to another bubble.

Abstract: The present invention is directed to an ophthalmic solution for soft contact lenses for controlled release of polyethers into an eye's tear film. Polyether components of the subject ophthalmic solution are released from the soft contact lens material matrix over long time periods to produce longer lasting wetting performance, improved lubricity, improved end-of-the-day comfort and reduced feeling of dryness from wearing contact lenses.

Abstract: The present invention relates to an aqueous bubble solution. The solution has at least a surfactant that produces micelles in an aqueous solution, along with an ionic, hydrophobic or hydrogen bonding agent that interacts with the surfactant. When the bubble solution is formed into a bubble the bubble provides a first predetermined effect other than just being formed and popping.

Abstract: Ophthalmic compositions include a polycation material to enhance antimicrobial efficacy against bacteria such as E. coli. The compositions include eye drop and contact lens treating solutions. A preferred polycation material is cationic cellulose derivatives.

Abstract: Ophthalmic compositions such as eye drop and contact lens treating solutions include a polycationic material to enhance antimicrobial efficacy against protozoans such as acanthamoebae. One preferred class of polycationic materials is cationic cellulose derivatives.

Abstract: Fluorinated side-chain siloxane copolymeric matrix controlled diffusion drug delivery systems are provided that allow controlled release of sustained concentrations of therapeutic agents within a treated area for a prolonged period of time. The favorable solubility characteristics of the fluorinated side-chains of the siloxane copolymeric matrix controlled diffusion drug delivery systems allow for manipulation of drug release rates depending on the particular therapeutic use and the particular needs of the patient.